What is MR-100A-01 used for?

MR-100A-01 is indicated for Type 2 diabetes.

Who makes MR-100A-01?

MR-100A-01 is developed by Mylan Technologies Inc..

What are the side effects of MR-100A-01?

Common side effects include Nausea, Diarrhea, Vomiting.

Last reviewed 2026-04-23 · How we verify

MR-100A-01

Mylan Technologies Inc. · Phase 3 active Small molecule

MR-100A-01 is a small molecule drug that targets the SGLT2 receptor.

MR-100A-01 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic name	MR-100A-01
Also known as	Transdermal contraceptive delivery system
Sponsor	Mylan Technologies Inc.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 3

Mechanism of action

By inhibiting SGLT2, MR-100A-01 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.

Approved indications

Type 2 diabetes

Common side effects

Nausea
Diarrhea
Vomiting

Key clinical trials

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MR-100A-01 CI brief — competitive landscape report
MR-100A-01 updates RSS · CI watch RSS
Mylan Technologies Inc. portfolio CI